World Stents Market Examined in New Cutting-Edge Research Report by Kalorama Information

29 Nov 2012 • by Natalie Aster

Coronary stents are primarily constructed of inert materials such as metals, alloys and, more recently, biodegradable polymers. There are two major types of reduce the risk of late stent thrombosis even in patients undergoing short-term durations of dual anti-platelet therapy. The company obtained CE marking for two anti-CD34 antibodies-coated stents, Genous Stainless Steel and Genous Cobalt-Chromium. Despite the attractive properties of the EPC technology, the stent’s clinical efficacy did not improve in comparison to newer generations of drug-eluting stents; the late lumen loss observed with this stent in several clinical trials was above 0.6 mm in many cases, which is actually considerably higher than that achieved with newer stents.

Besides the high late loss, the Trias HR study also reported a higher target vessel failure than that observed in patients treated with Taxus. According to the report “The World Market for Stents (Drug-Eluting and Bare Metal Product Markets in US, EU, Japan, India, China and ROW)” by Kalorama Information as the CD34 markers are not specific to endothelial progenitor cells exclusively, but are shared by other hematopoietic cells, a better understanding of the cellular processes would benefit the development of this EPC capturing technology for applications on stents.

Report Details:

The World Market for Stents (Drug-Eluting and Bare Metal Product Markets in US, EU, Japan, India, China and ROW)
Published: October, 2012
Pages: 164
Price: US$ 3.995,00

Despite these disappointing results, the EPC technology appears to perform better when used as dual therapy in combination with an anti-proliferative drug. The Combo Stent, also developed by OrbusNeich, has an abluminal coating composed of sirolimus and a biodegradable polymer, in addition to anti-CD34 antibodies. Due to this combination, the Combo Stent is expected to simultaneously reduce the risk of re-stenosis and enhance the vessel healing process. The Combo Stent is currently evaluated in comparison with Taxus Liberte in the randomized clinical trial Remedee in Australia.

More information can be found in the report “The World Market for Stents (Drug-Eluting and Bare Metal Product Markets in US, EU, Japan, India, China and ROW)” by Kalorama Information.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com